PDX model details
PDX ID | 472M Cx |
---|---|
Host Strain(and Source) | NSG Source: Monash University |
Host Strain Immune system Humanized | NO |
Host Type | Castrate |
Graft Site | Subcutaneous |
Current Generation (* indicates number of generations grown in Castrate host) |
10 (5*) |
Average PDX Generation Time (days +/- SEM) | 51 ± 3 |
Tumor preparation | Tumor solid |
Tumor Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
Tumor confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
Passage QA performed | Routine QA every 2-3 passages |
Associated meta data | |
PDX model availability | Yes (fixed, frozen) |
Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
Pubmed ID | 34413304 |
Markers | 472M Cx |
---|---|
AR | N |
PSA | N |
PSMA | N |
NE | Y |
ERG | N |
This table displays curated CNVs
PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
---|---|---|---|---|---|---|---|
472M Cx | ZFHX3 | -1.29048 | 0.81763 | loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
472M Cx | TP53 | -1.20961 | 0.864771 | loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
472M Cx | RB1 | -25.4079 | 0.0000000449 | homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
472M Cx | PTEN | -2.22538 | 0.427685 | loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
472M Cx | NCOR1 | -1.29767 | 0.813565 | loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
472M Cx | FANCA | -1.29048 | 0.81763 | loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
472M Cx | CHD7 | 0.53139 | 2.89064 | gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
472M Cx | CDH1 | -1.29048 | 0.81763 | loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
472M Cx | BRCA1 | -1.26655 | 0.831305 | loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
Sample Number | 472M |
---|---|
Sample Site | Left ilium |
Sample source | Biopsy |
Pathology Tumor Diagnosis | None |
Gleason Score | None |
Primary Gleason Score | None |
Secondary Gleason Score | None |
Tertiary Gleason Score | None |
ISUP Grade Group | |
Tumor Grade | |
D'Amico Risk Classification | |
Tumor Volume (in cc) | 0.0 |
Treatment Prior to Specimen Collection | ADT, docetaxel |
Patient Information
Patient Number | 472 |
---|---|
Sex | Male |
Diagnosis | Prostate Cancer |
PSA at diagnosis (ng/mL) | 630 |
Consent to share data | |
Patient Tumor Collection (Current Model) | |
---|---|
Tumour sample ID | 472M |
Patient Age (binned in 5 year age groups) | 50-54 |
This table displays curated sequence variants
The table can be sorted by any field. However, please note that when you click on a column header to sort, there might be a brief delay
The table can be sorted by any field. However, please note that when you click on a column header to sort, there might be a brief delay
PDX ID | Gene Symbol | Depth | ALT_FREQ | Consequence | Exon | GnomAD_AF | CADD_PHRED | Clinvar_clnsig | Platform | Experiments Name | Reference | Library Type | Instrument Type |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
472M Cx | SRC | 535 | 0.68 | missense_variant | '12/14 | 8.15E-06 | 25.1 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
472M Cx | GPR158 | 736 | 0.58 | stop_gained | '11/11 | 8.19E-06 | 36 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
472M Cx | CTNNB1 | 526 | 0.57 | missense_variant | '3/15 | 4.07E-06 | 28.6 | Pathogenic/Likely_pathogenic,_other | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
No information in Gene expression
No information in Drug dosing Table